Annie Pierre Jonville-Bera

Annie Pierre Jonville-Bera

Auto-generated profile, based on publicly available information

Annie Pierre Jonville-Bera

Service de pharmacosurveillance, centre régional de pharmacovigilance Centre Val de Loire, CHRU, Tours, Tours, France; Université de Tours, Université de Nantes, INSERM, methodS in Patients-centered outcomes and HEalth ResEarch (SPHERE)-UMR 1246, Tours, France

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2001 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
AJAnnie-Pierre Jonville-Béra
Annie-Pierre Jonville-Béra
EAElisabeth Autret-Leca
Elisabeth Autret-Leca
YGYves Gruel
Yves Gruel
High-molecular-weight hydroxyethyl starches (hetastarches) can cause acquired type I von Willebrand's disease.1 A case has also occurred after treatment with medium-molecular-weight hydroxyethyl starches (pentastarches).2 We analyzed all patients with hemostatic disorders that occurred during treatment with pentastarch (Elohes and Hesteril, Fresenius, Paris; and Lomol, Dupont, Wilmington, Del.) and that were spontaneously reported to the 31 French regional drug-monitoring centers.

12 April 2005 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
AJA. P. Jonville-Béra
A. P. Jonville-Béra
FBF. Béra
F. Béra
EAE. Autret-Leca
E. Autret-Leca

9 October 2021 in Rheumatology
Verified
Journal Article
Open access
PDF file
CMCamille Mettler
Camille Mettler
AJAnnie-Pierre Jonville-Bera
Annie-Pierre Jonville-Bera
AGAurélie Grandvuillemin
Aurélie Grandvuillemin
JTJean-Marc Treluyer
Jean-Marc Treluyer
BTBenjamin Terrier
Benjamin Terrier
LCLaurent Chouchana
Laurent Chouchana
Camille Mettler, Annie-Pierre Jonville-Bera, Aurélie Grandvuillemin, Jean-Marc Treluyer, Benjamin Terrier, Laurent Chouchana; Risk of giant cell arteritis and p

30 March 2009 in Critical Care
Verified
Journal Article
Open access
PDF file
ALAnnick Legras
Annick Legras
BGBruno Giraudeau
Bruno Giraudeau
AJAnnie-Pierre Jonville-Bera
Annie-Pierre Jonville-Bera
CCChristophe Camus
Christophe Camus
BFBruno François
Bruno François
EAElisabeth Autret-Leca
Elisabeth Autret-Leca
Introduction: We aimed to establish whether the use of nonsteroidal anti-inflammatory drugs (NSAIDs) during evolving bacterial community-acquired infection in adults is associated with severe sepsis or septic shock. Methods: We conducted a multicentre case-control study in eight intensive care units. Cases were all adult patients admitted for severe sepsis or septic shock due to a bacterial community-acquired infection. Control individuals were patients hospitalized with a mild community-acquired infection. Each case was matched to one control for age, presence of diabetes and site of infection. Results: The main outcome measures were the proportions of cases and controls exposed to NSAIDs or aspirin during the period of observation. In all, 152 matched pairs were analyzed. The use of NSAIDs or aspirin during the observation period did not differ between cases and controls (27% versus 28; odds ratio = 0.93, 95% confidence interval [CI] = 0.52 to 1.64). If aspirin was not considered or if a distinction was made between acute and chronic drug treatment, there remained no difference between groups. However, the median time to prescription of effective antibiotic therapy was longer for NSAID users (6 days, 95% CI = 3 to 7 days) than for nonusers (3 days, 95% CI = 2 to 3 days; P = 0.02). Conclusions: In this study, the use of NSAIDs or aspirin during evolving bacterial infection was frequent and occurred in one-quarter of the patients with such infection. Although the use of NSAIDs by patients with severe sepsis or septic shock did not differ from their use by those with mild infection at the same infected site, we observed a longer median time to prescription of effective antibiotic therapy in NSAID users.

1 March 2001 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
AJAnnie‐Pierre Jonville‐Béra
Annie‐Pierre Jonville‐Béra
EAElisabeth Autret‐Leca
Elisabeth Autret‐Leca
FBFlorence Barbeillon
Florence Barbeillon
JPJosepha Paris‐Llado
Josepha Paris‐Llado
TSThe French Reference Centers For Sids
The French Reference Centers For Sids

7 September 2022 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
MLMarie‐Laure Laroche
Marie‐Laure Laroche
SGSophie Gautier
Sophie Gautier
EPElisabeth Polard
Elisabeth Polard
MRMarie-Blanche Valnet Rabier
Marie-Blanche Valnet Rabier
LCLaurent Chouchana
Laurent Chouchana
FGfor the IATROSTAT study group
for the IATROSTAT study group
Aims: In the last French study in 2007, the incidence of hospital admissions (HAs) related to adverse drug reactions (ADRs) was 3.6%. The objective was to assess the current ADR‐HA incidence in France and to describe both its characteristics and preventability.Methods: A prospective multicentre study was conducted among randomly selected French public hospital medical wards (April–July 2018). Patients admitted during a week period were included. ADR‐HA cases were collected by the French Regional Pharmacovigilance Centres network. An independent committee validated potential cases and ADR preventability.Results: ADR‐HA incidence was 8.5% (95% confidence interval [CI]: 7.6–9.4%), increasing with age (3.3% [95%CI: 1.8–5.5%] ≤16 y vs. 10.6% [95%CI: 9.3–12.0%] ≥65 y). The most common ADRs were haemorrhagic events (8.8%), haematological disorders (6.5%), acute renal failure (6.3%), fluid and electrolyte disorders (6.0%), and falls (5.2%). New drugs were involved: targeted therapies (22.8% of antineoplastics), direct oral anticoagulants (29.6% of antithrombotics) and incretin‐based drugs (20.0% of antidiabetics). ADRs were preventable in 16.1% of cases because the drugs involved had not been used in accordance with monographies, package leaflets or other therapeutic guidelines. The main situations of noncompliance addressed either dose or duration of use (27.9%), warning (23.2%), use precaution (18.6%) and inappropriate self‐medication or misuse by patients (11.6%).Conclusion: In France, ADR‐HA incidence dramatically increased over the last decade. A significant proportion was related to new pharmacological classes and considered as preventable. These findings should lead to in‐depth thought on preventive actions on at‐risk drug classes.